Tablets vs Injections: Oral and Injectable GLP-1s Compared

GLP-1 medicines for weight management now come in two forms in the UK: weekly injections, such as Mounjaro (tirzepatide) and Wegovy (semaglutide), and once-daily tablets, such as Wegovy tablets (oral semaglutide) and Foundayo (orforglipron). Both act on the same appetite pathways and cause similar side effects. The main differences lie in how much weight people lost on average in the trials, how often you take them, the rules around food, and the length of the safety record. This guide sets out the evidence for both so you can have an informed conversation with a prescriber.

Why a tablet form matters

For most of the past decade, GLP-1 treatment for weight management meant an injection. Liraglutide (Saxenda) was a daily injection; semaglutide (Wegovy) and tirzepatide (Mounjaro) cut that to once a week. For many people a weekly pen is perfectly manageable, but a needle is a real barrier for others, and injectable pens have strict storage and travel requirements.

Tablets change that equation. They can be kept at room temperature (always check the patient information leaflet for your specific product), they can be carried easily, and they take away the need to inject. Tablets may also prove easier to manufacture at scale than injectable pens, which could matter for supply over the long term, although that is a prediction rather than an established fact.

The trade-off is that a tablet is a daily commitment, and for oral semaglutide in particular, a fussy one. Swapping a weekly needle for a daily routine does not suit everyone. To understand the choice properly, it helps to look at how each form works.

For a broader introduction to the tablet options, see our complete guide to oral GLP-1 medicines and the oral GLP-1 hub.

How the two forms work

Same target, different delivery

GLP-1 (glucagon-like peptide-1) is a hormone released by the gut after eating. It signals fullness to the brain, slows the emptying of the stomach and helps the pancreas release insulin when blood glucose is high. GLP-1 receptor agonists mimic this hormone, but last much longer than the natural version.

Injectable semaglutide and tirzepatide are peptides: chains of amino acids. Peptides are broken down by stomach acid and digestive enzymes, so they are normally injected under the skin, from where they are absorbed slowly over days. Tirzepatide also acts on a second receptor, GIP (glucose-dependent insulinotropic polypeptide), which is one reason it is called a "dual agonist". You can read more in how Mounjaro works.

Oral semaglutide: a peptide in a protective package

Oral semaglutide is the same molecule as Wegovy and Ozempic injections. To get it through the stomach, it is combined with an absorption enhancer called SNAC (salcaprozate sodium), which briefly raises the local pH and helps a small fraction of the dose cross the stomach lining. Even so, only a small proportion of each tablet is absorbed. That is why the daily tablet doses (in milligrams) are much higher than the weekly injection doses, and why the timing rules matter so much: food, drink or other medicines in the stomach can sharply reduce absorption.

Orforglipron: a small molecule

Orforglipron, sold as Foundayo, is not a peptide. It is a "small-molecule" drug, chemically closer to a conventional tablet, designed to activate the GLP-1 receptor. Because it is absorbed like most ordinary medicines, it does not need to be taken on an empty stomach. This is the main practical difference between the two tablets. Our Foundayo guide explains the science in more detail.

UK licensing status at the time of writing

Regulatory status has changed quickly in 2025 and 2026, so treat the table below as a snapshot and check the MHRA and the current Summary of Product Characteristics (SmPC) on medicines.org.uk before relying on it.

A licence from the MHRA means a medicine can be prescribed for that use. A NICE recommendation is a separate decision about whether the NHS in England should fund it. That is why a medicine can be available privately but not on the NHS. Our guides to Mounjaro on the NHS and Wegovy on the NHS explain how NHS access currently works for the injections.

What the trials show

The main placebo-controlled trials

The figures below come from separate trials, each comparing a medicine with placebo. The participants, trial lengths and statistical approaches differ, so these numbers cannot be compared like for like. They give a sense of scale, not a league table.

A few points help with interpreting these results.

• Two ways of counting. Many recent trials report two figures. One includes everyone who started, whether or not they kept taking the medicine (a "treatment policy" or "treatment regimen" estimate). The other estimates what happens if people take the medicine as intended (an "efficacy" or "trial product" estimate). The second figure is always higher. Where a range appears above, that is why.
• The 50mg dose. The 50mg oral semaglutide dose studied in OASIS 1 is not the dose licensed in the UK. The UK Wegovy tablet licence uses a maximum of 25mg, based on OASIS 4.
• Orforglipron dose labels. The doses used in ATTAIN-1 were labelled differently from the strengths marketed as Foundayo. Your prescriber and the SmPC are the authority on how the marketed strengths relate to the trial doses.
• Averages hide a wide spread. In every trial, some people lost far more than the average and some lost very little. Our guide to realistic weight loss expectations looks at this spread.

Is there a head-to-head trial of tablet versus injection?

Not for weight management, at the time of writing. The only large head-to-head trial among the main weight-loss medicines is SURMOUNT-5, which compared tirzepatide and semaglutide injections and found greater average weight loss with tirzepatide. Comparisons between tablets and injections therefore rely on placing separate trials side by side, which is always less reliable. See our analysis of SURMOUNT-5.

Side effects: tablets are not a "lighter" option

It is a common assumption that a tablet will be gentler than an injection. The evidence does not support that. Because tablets and injections act on the same receptors, they share the same side-effect profile.

Common side effects with both forms

• Nausea, especially in the first weeks and after each dose increase
• Vomiting
• Diarrhoea or constipation
• Indigestion, reflux, burping and bloating
• Tiredness and headache
• Reduced appetite (the intended effect, but it can make eating enough difficult)

In OASIS 4, nausea was reported by just under half of people taking oral semaglutide 25mg and vomiting by around three in ten, compared with much lower rates on placebo. Most episodes were mild to moderate and settled over time. In ATTAIN-1, gastrointestinal side effects were again the most common, and they were the main reason people stopped orforglipron early. Rates rose at higher doses.

Differences between the forms

• Injection-site reactions (redness, itching, bruising) occur only with injections.
• Day-to-day pattern. Some people on weekly injections notice side effects that peak a day or two after their dose. With daily tablets, drug levels are steadier across the week, although whether this makes side effects easier for individuals is not well established.
• Stopping quickly. If side effects become intolerable, a tablet leaves the body faster than a weekly injection, which lasts for several weeks after the final dose. Semaglutide itself is long-acting in both forms, so this difference is less marked for oral semaglutide than for orforglipron.

Serious side effects to know about

These apply to the whole class: pancreatitis (inflammation of the pancreas), gallbladder problems such as gallstones, dehydration leading to kidney problems (especially with prolonged vomiting or diarrhoea), and low blood sugar in people also taking insulin or sulfonylureas for diabetes. The MHRA has also advised that people who could become pregnant should use effective contraception while taking these medicines, and that tirzepatide may reduce the effectiveness of oral contraceptives in some circumstances. For a full breakdown of the tablet side-effect evidence, see oral GLP-1 side effects, and for practical tips, our guide to managing nausea on GLP-1 medication.

Daily life: routine, food and travel

Taking oral semaglutide

Oral semaglutide comes with strict instructions, which are set out in the patient information leaflet. In general terms:

• Take the tablet on an empty stomach, usually first thing in the morning.
• Swallow it whole with only a small sip of plain water (the leaflet gives the maximum volume).
• Wait for the specified time, usually at least 30 minutes, before eating, drinking anything else or taking other oral medicines.

Getting this wrong does not cause harm, but it can mean very little of the medicine is absorbed. For people who take several morning medicines, such as thyroid tablets, this needs careful planning with a pharmacist. More detail is in our oral semaglutide guide.

Taking orforglipron

Orforglipron can be taken at any time of day, with or without food. That makes it simpler than oral semaglutide, though it still needs to be taken every day. The SmPC sets out what to do if you miss a dose and any interactions to be aware of.

Taking a weekly injection

Weekly injections involve one injection on the same day each week, using a pre-filled pen. There is a learning curve, but most people find it quick after the first few doses. Pens need to be refrigerated before first use and kept within temperature limits afterwards, which matters for travel. See how to use the Mounjaro KwikPen and how to use the Wegovy FlexTouch pen.

Which routine is easier to stick to?

There is no single answer. In general, medicines taken less often tend to be easier to take consistently, which favours a weekly injection. On the other hand, someone with a strong aversion to needles may find a daily tablet far more acceptable. A useful question to ask yourself is which you are more likely to keep doing, reliably, for a year or more, because the trials show that weight tends to return when treatment stops.

Dose schedules compared

All GLP-1 medicines start low and increase gradually, usually every four weeks, to give the gut time to adjust. Doses below reflect UK product information at the time of writing; always follow your prescriber and the current SmPC.

The MHRA has also authorised a higher Wegovy injection dose of up to 7.2mg weekly for some adults with obesity (BMI of 30 or more). Whether a person is suitable is a decision for the prescriber.

Cost: what affects it

We do not quote prices in our guides, because they change often and differ between providers. Several factors affect what you pay privately for either form:

• The medicine and dose. Some providers charge the same at every dose; others charge more at higher doses.
• List prices. Manufacturers set list prices, and these can change. In September 2025, for example, the UK list price of Mounjaro rose, which affected private prices across the market.
• Newer medicines. Tablets launched in 2026 may be priced differently from established injections, and early pricing can shift.
• What is included. Clinical support, follow-up consultations, needles and sharps bins, and delivery are bundled differently by different providers.
• Daily versus weekly supply. Tablets are usually supplied in monthly packs; injections in pens holding several weekly doses.

To compare current costs, see our price comparison, and for the bigger picture, the long-term cost of GLP-1 treatment.

Who might a prescriber consider for each form?

These are general considerations, not recommendations. A prescriber will weigh your full medical history.

Situations where a tablet may be discussed

• A strong fear of or aversion to needles
• Difficulty injecting, for example due to reduced hand dexterity (although tablets have their own handling issues)
• Frequent travel where keeping pens within temperature limits is difficult
• A wish to move from injectable semaglutide to an equivalent oral form, where the licence supports this

Situations where an injection may be discussed

• Wanting the option with the largest average effect in trials (tirzepatide)
• Difficulty with a strict daily routine, or a busy morning with several other medicines (relevant to oral semaglutide)
• Wanting a medicine with a longer track record and established NHS pathways
• Problems swallowing tablets

Who should not take either form

The cautions and contraindications are broadly shared. GLP-1 medicines are generally not suitable during pregnancy or breastfeeding, and caution or avoidance applies with a history of pancreatitis, certain thyroid cancers in the personal or family history, severe gastrointestinal disease, or some eating disorders. Our guide to who should not take GLP-1 medications covers this in detail.

Switching between forms

People sometimes ask whether they can move from an injection to a tablet once their weight has stabilised, or vice versa. The Wegovy tablet licence describes switching people on semaglutide 2.4mg injections directly to the 25mg tablet. Switching from tirzepatide to a tablet, or from a tablet to an injection, involves a different medicine and a judgement about the right starting dose. A prescriber should plan any switch. Our guide to switching from an injection to a tablet explains the considerations.

Long-term evidence and what remains uncertain

Injectable semaglutide has the longest safety record among the newer medicines, including the SELECT cardiovascular outcomes trial in people with established heart disease. Tirzepatide has extensive data from the SURMOUNT and SURPASS programmes. Oral semaglutide has been used for type 2 diabetes (as Rybelsus) since 2019 in the UK and has its own cardiovascular trials in diabetes, but the higher weight-management doses are newer. Orforglipron is the newest of all, so the real-world safety record is still being built.

Several questions remain open at the time of writing:

• How tablets and injections compare directly in the same people over the long term
• Whether daily tablets are taken as consistently as weekly injections in everyday life
• Whether NICE will recommend tablets for NHS use, and under what criteria
• How weight changes after stopping a tablet compared with stopping an injection (for the injections, trials such as STEP 4 and SURMOUNT-4 showed substantial regain after stopping; see weight regain after stopping GLP-1 medication)

When to speak to a professional

Talk to your GP, pharmacist or prescriber before starting, switching or stopping any GLP-1 medicine, and if you are unsure which form suits you. They can check for interactions with your other medicines, which matters especially with oral semaglutide's timing rules. Tell them about any history of pancreatitis, gallbladder disease, thyroid problems, kidney problems, diabetic eye disease or eating disorders, and if you are pregnant, planning pregnancy or breastfeeding.

Seek urgent medical help, through NHS 111 or by calling 999 in an emergency, if you experience:

• Severe, persistent abdominal pain, sometimes spreading to the back, with or without vomiting (a possible sign of pancreatitis)
• Pain in the upper right abdomen, fever, or yellowing of the skin or eyes (possible gallbladder problems)
• Vomiting or diarrhoea that prevents you keeping fluids down, or signs of dehydration such as very little urine, dizziness or confusion
• Signs of a severe allergic reaction, such as swelling of the face or throat or difficulty breathing
• Symptoms of low blood sugar if you also take diabetes medicines such as insulin or a sulfonylurea

You can also report suspected side effects to the MHRA through the Yellow Card scheme. For an overview of regulated online services, see our provider comparison.